Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lilly Wants to Double China Revenues; Seeks Distribution Partners

publication date: Mar 21, 2012
Lilly, which reported its China revenues climbed 31% in 2011, hopes to raise the China contribution to its total revenues from a current 2% up to 4%. In dollars, that will bring the company from about $500 million to $1 billion in China revenues. “Our goal is to be the fastest growing pharmaceutical company in China,” CEO John Lechleiter said in a recent Beijing briefing. “We are increasing our investments in every aspect of our business.” Taking an unusual path for a big pharma, Lilly also said it hopes to form partnerships with China drug distributors. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital